121 results on '"Gomis, R"'
Search Results
2. Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study
- Author
-
García-Escobar, E., Valdés, S., Soriguer, F., Vendrell, J., Urrutia-Etxebarria, I. M., Maldonado-Araque, C., Ortega, E., Ocón, P., Montanya, E., Menéndez, E., Lago-Sampedro, A., González-Frutos, T., Gomis, R., Goday, A., García-Serrano, S., Galán-García, J. L., Castell, C., Bordiú, E., Badía, R., Aguilera-Venegas, G., Girbés, J., Gaztambide, S., Delgado, E., Chaves, F. J., Castaño, L., Calle-Pascual, A., Rojo-Martínez, G., and Franch-Nadal, J.
- Published
- 2021
- Full Text
- View/download PDF
3. Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04)
- Author
-
Coleman, R.E., Collinson, M., Gregory, W., Marshall, H., Bell, R., Dodwell, D., Keane, M., Gil, M., Barrett-Lee, P., Ritchie, D., Bowman, A., Liversedge, V., De Boer, R.H., Passos-Coelho, J.L., O'Reilly, S., Bertelli, G., Joffe, J., Brown, J.E., Wilson, C., Tercero, J.C., Jean-Mairet, J., Gomis, R., and Cameron, D.
- Published
- 2018
- Full Text
- View/download PDF
4. Aspectos metodológicos de los procesos asistenciales integrados (PAI)
- Author
-
Gomis, R., Mata Cases, M., Mauricio Puente, D., Artola Menéndez, S., Ena Muñoz, J., Mediavilla Bravo, J.J., Miranda Fernández-Santos, C., Orozco Beltrán, D., Rodríguez Mañas, L., Sánchez Villalba, C., and Martínez, J.A.
- Published
- 2017
- Full Text
- View/download PDF
5. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort di@bet.es study
- Author
-
Rojo-Martínez, G., Valdés, S., Soriguer, F., Vendrell, J., Urrutia, I., Pérez, V., Ortega, E., Ocón, P., Montanya, E., Menéndez, E., Lago-Sampedro, A., González- Frutos, T., Gomis, R., Goday, A., García-Serrano, S., García-Escobar, E., Galán-García, J. L., Castell, C., Badía-Guillén, R., Aguilera-Venegas, G., Girbés, J., Gaztambide, S., Franch-Nadal, J., Delgado, E., Chaves, F. J., Castaño, L., and Calle-Pascual, A.
- Published
- 2020
- Full Text
- View/download PDF
6. Following the results of the EMPA-REG OUTCOME trial with empagliflozin, is it possible to speak of a class effect?
- Author
-
Ampudia-Blasco FJ, Romera I, Ariño B, and Gomis R
- Subjects
cardiovascular ,outcome studies ,SGLT2 inhibitors ,empagliflozin ,dapagliflozin ,canagliflozin. ,Medicine (General) ,R5-920 - Abstract
Francisco Javier Ampudia‑Blasco,1 Irene Romera,2 Bernat Ariño,3 Ramón Gomis4 1Endocrinology and Nutrition Department, Clinic University Hospital Valencia, Valencia, Spain; 2Eli Lilly and Company España, Madrid, Spain; 3Boehringer Ingelheim España, Barcelona, Spain; 4Endocrinology Department, Hospital Clinic Barcelona, Barcelona, Spain Background: The recently published cardiovascular outcomes data for the first sodium–glucose cotransporter 2 (SGLT2) inhibitor, empagliflozin, have shown cardiovascular safety and additional benefits in patients with type 2 diabetes and established cardiovascular disease. Empagliflozin showed lower rates of death from cardiovascular causes or from any causes and lower hospitalization rates from heart failure compared with placebo, both in addition to standard care. This commentary discusses the existence of a possible class effect considering the available evidence described for other SGLT2 inhibitors. Main text: Empagliflozin, dapagliflozin and canagliflozin share the same mechanism of action, and it is a plausible hypothesis that some of the benefits of empagliflozin treatment could also be expected from other SGLT2 inhibitors. However, the rapid and persistent occurrence of cardiovascular benefits observed with empagliflozin and the different results shown by the three inhibitors in meta-analyses of some of their respective Phase II and III trials might suggest another possible mechanism of action, perhaps related to the different selectivity to inhibit SGLT-2 and other SGLT family members that these compounds present. Conclusion: There is still lack of evidence to answer whether the cardiovascular benefits observed with empagliflozin in the EMPA-REG OUTCOME study could be seen as a “class effect”, which is also attributable to dapagliflozin and canagliflozin. Keywords: cardiovascular, outcome studies, SGLT2 inhibitors, empagliflozin, dapagliflozin, canagliflozin
- Published
- 2017
7. Role of sodium tungstate as a potential antiplatelet agent
- Author
-
Fernández-Ruiz R, Pino M, Hurtado B, García de Frutos P, Caballo C, Escolar G, Gomis R, and Diaz-Ricart M
- Subjects
Therapeutics. Pharmacology ,RM1-950 - Abstract
Rebeca Fernández-Ruiz,1,2 Marc Pino,3 Begoña Hurtado,4 Pablo García de Frutos,4 Carolina Caballo,3 Ginés Escolar,3 Ramón Gomis,1,2,5 Maribel Diaz-Ricart3 1Diabetes and Obesity Research Laboratory, Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Rosellón, Barcelona, 2Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas, Barcelona, 3Hemotherapy–Hemostasis, Hospital Clínic, Universidad de Barcelona, IDIBAPS, Villarroel, Barcelona, 4Institutode Investigaciones Biomédicas de Barcelona, Consejo Superior de Investigaciones Científicas, Institut d’Investigacions Biomediques August Pi i Sunyer, Rosellón, Barcelona, 5Hospital Clinic, Universitat de Barcelona, Villarroel, Barcelona, Spain Purpose: Platelet inhibition is a key strategy in the management of atherothrombosis. However, the large variability in response to current strategies leads to the search for alternative inhibitors. The antiplatelet effect of the inorganic salt sodium tungstate (Na2O4W), a protein tyrosine phosphatase 1B (PTP1B) inhibitor, has been investigated in this study.Methods: Wild-type (WT) and PTP1B knockout (PTP1B-/-) mice were treated for 1 week with Na2O4W to study platelet function with the platelet function analyzer PFA-100, a cone-and-plate analyzer, a flat perfusion chamber, and thrombus formation in vivo. Human blood aliquots were incubated with Na2O4W for 1 hour to measure platelet function using the PFA-100 and the annular perfusion chamber. Aggregometry and thromboelastometry were also performed.Results: In WT mice, Na2O4W treatment prolonged closure times in the PFA-100 and decreased the surface covered (%SC) by platelets on collagen. Thrombi formed in a thrombosis mice model were smaller in animals treated with Na2O4W (4.6±0.7 mg vs 8.9±0.7 mg; P
- Published
- 2015
8. Syndrome de Raynaud
- Author
-
Gomis, R., primary, Lallemand, B., additional, Vaienti, L., additional, and Merle, M., additional
- Published
- 2017
- Full Text
- View/download PDF
9. Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue
- Author
-
Universitat Rovira i Virgili, Gonzalez-Franquesa A; Gama-Perez P; Kulis M; Szczepanowska K; Dahdah N; Moreno-Gomez S; Latorre-Pellicer A; Fernández-Ruiz R; Aguilar-Mogas A; Hoffman A; Monelli E; Samino S; Miró-Blanch J; Oemer G; Duran X; Sanchez-Rebordelo E; Schneeberger M; Obach M; Montane J; Castellano G; Chapaprieta V; Sun W; Navarro L; Prieto I; Castaño C; Novials A; Gomis R; Monsalve M; Claret M; Graupera M; Soria G; Wolfrum C; Vendrell J; Fernández-Veledo S; Enríquez JA; Carracedo A; Perales JC; Nogueiras R; Herrero L; Trifunovic A; Keller MA; Yanes O; Sales-Pardo M; Guimerà R; Blüher M; Martín-Subero JI; Garcia-Roves PM, Universitat Rovira i Virgili, and Gonzalez-Franquesa A; Gama-Perez P; Kulis M; Szczepanowska K; Dahdah N; Moreno-Gomez S; Latorre-Pellicer A; Fernández-Ruiz R; Aguilar-Mogas A; Hoffman A; Monelli E; Samino S; Miró-Blanch J; Oemer G; Duran X; Sanchez-Rebordelo E; Schneeberger M; Obach M; Montane J; Castellano G; Chapaprieta V; Sun W; Navarro L; Prieto I; Castaño C; Novials A; Gomis R; Monsalve M; Claret M; Graupera M; Soria G; Wolfrum C; Vendrell J; Fernández-Veledo S; Enríquez JA; Carracedo A; Perales JC; Nogueiras R; Herrero L; Trifunovic A; Keller MA; Yanes O; Sales-Pardo M; Guimerà R; Blüher M; Martín-Subero JI; Garcia-Roves PM
- Abstract
Metabolic plasticity is the ability of a biological system to adapt its metabolic phenotype to different environmental stressors. We used a whole-body and tissue-specific phenotypic, functional, proteomic, metabolomic and transcriptomic approach to systematically assess metabolic plasticity in diet-induced obese mice after a combined nutritional and exercise intervention. Although most obesity and overnutrition-related pathological features were successfully reverted, we observed a high degree of metabolic dysfunction in visceral white adipose tissue, characterized by abnormal mitochondrial morphology and functionality. Despite two sequential therapeutic interventions and an apparent global healthy phenotype, obesity triggered a cascade of events in visceral adipose tissue progressing from mitochondrial metabolic and proteostatic alterations to widespread cellular stress, which compromises its biosynthetic and recycling capacity. In humans, weight loss after bariatric surgery showed a transcriptional signature in visceral adipose tissue similar to our mouse model of obesity reversion. Overall, our data indicate that obesity prompts a lasting metabolic fingerprint that leads to a progressive breakdown of metabolic plasticity in visceral adipose tissue.
- Published
- 2022
10. Correction: The anti-metastatic activity of collagenase-2 in breast cancer cells is mediated by a signaling pathway involving decorin and miR-21
- Author
-
Soria-Valles, C, Gutiérrez-Fernández, A, Guiu, M, Mari, B, Fueyo, A, Gomis, R R, and López-Otín, C
- Published
- 2019
- Full Text
- View/download PDF
11. Our journal is 65 years-old: A look back at the past
- Author
-
Corcoy, R, Lucas, A, Gomis, R, Mauricio, D, Wagner, A, Jimenez, A, Fajardo, C, Ballesteros, M, Gimeno, JA, and Zafon, C
- Published
- 2022
12. Targeted immunotherapy against distinct cancer-associated fibroblasts overcomes treatment resistance in refractory HER2+breast tumors
- Author
-
Rivas E, Linares J, Zwick M, Gomez-Llonin A, Guiu M, Labernadie A, Badia-Ramentol J, Llado A, Bardia L, Perez-Nunez I, Martinez-Ciarpaglini C, Tarazona N, Sallent-Aragay A, Garrido M, Celia-Terrassa T, Burgues O, Gomis R, Albanell J, and Calon A
- Abstract
A substantial proportion of HER2+ breast cancer patients do not benefit from HER2-targeted therapy. Here, the authors identify a population of cancer-associated fibroblasts involved in the suppression of trastuzumab-induced ADCC that can be pharmacologically targeted to raise treatment effectiveness in unresponsive tumors. About 50% of human epidermal growth factor receptor 2 (HER2)+ breast cancer patients do not benefit from HER2-targeted therapy and almost 20% of them relapse after treatment. Here, we conduct a detailed analysis of two independent cohorts of HER2+ breast cancer patients treated with trastuzumab to elucidate the mechanisms of resistance to anti-HER2 monoclonal antibodies. In addition, we develop a fully humanized immunocompetent model of HER2+ breast cancer recapitulating ex vivo the biological processes that associate with patients' response to treatment. Thanks to these two approaches, we uncover a population of TGF-beta-activated cancer-associated fibroblasts (CAF) specific from tumors resistant to therapy. The presence of this cellular subset related to previously described myofibroblastic (CAF-S1) and podoplanin+ CAF subtypes in breast cancer associates with low IL2 activity. Correspondingly, we find that stroma-targeted stimulation of IL2 pathway in unresponsive tumors restores trastuzumab anti-cancer efficiency. Overall, our study underscores the therapeutic potential of exploiting the tumor microenvironment to identify and overcome mechanisms of resistance to anti-cancer treatment.
- Published
- 2022
13. Type 2 diabetes preventive effects with a 12-months sardine-enriched diet in elderly population with prediabetes: An interventional, randomized and controlled trial
- Author
-
Díaz-Rizzolo, D.A., primary, Serra, A., additional, Colungo, C., additional, Sala-Vila, A., additional, Sisó-Almirall, A., additional, and Gomis, R., additional
- Published
- 2021
- Full Text
- View/download PDF
14. Fatty liver index as a predictor for type 2 diabetes in subjects with normoglycemia in a nationwide cohort study
- Author
-
Universitat Rovira i Virgili, Garcia-Escobar, E.; Valdes, S.; Soriguer, F.; Vendrell, J.; Urrutia-Etxebarria, I. M.; Maldonado-Araque, C.; Ortega, E.; Ocon, P.; Montanya, E.; Menendez, E.; Lago-Sampedro, A.; Gonzalez-Frutos, T.; Gomis, R.; Goday, A.; Garcia-Serrano, S.; Galan-Garcia, J. L.; Castell, C.; Bordiu, E.; Badia, R.; Aguilera-Venegas, G.; Girbes, J.; Gaztambide, S.; Delgado, E.; Chaves, F. J.; Castano, L.; Calle-Pascual, A.; Rojo-Martinez, G.; Franch-Nadal, J., Universitat Rovira i Virgili, and Garcia-Escobar, E.; Valdes, S.; Soriguer, F.; Vendrell, J.; Urrutia-Etxebarria, I. M.; Maldonado-Araque, C.; Ortega, E.; Ocon, P.; Montanya, E.; Menendez, E.; Lago-Sampedro, A.; Gonzalez-Frutos, T.; Gomis, R.; Goday, A.; Garcia-Serrano, S.; Galan-Garcia, J. L.; Castell, C.; Bordiu, E.; Badia, R.; Aguilera-Venegas, G.; Girbes, J.; Gaztambide, S.; Delgado, E.; Chaves, F. J.; Castano, L.; Calle-Pascual, A.; Rojo-Martinez, G.; Franch-Nadal, J.
- Abstract
Our aim was to evaluate whether fatty liver index (FLI) is associated with the risk of type 2 diabetes (T2DM) development within the Spanish adult population and according to their prediabetes status; additionally, to examine its incremental predictive value regarding traditional risk factors. A total of 2260 subjects (Prediabetes: 641 subjects, normoglycemia: 1619 subjects) from the Di@bet.es cohort study were studied. Socio-demographic, anthropometric, clinical data and survey on habits were recorded. An oral glucose tolerance test was performed and fasting determinations of glucose, lipids and insulin were made. FLI was calculated and classified into three categories: Low (< 30), intermediate (30-60) and high (> 60). In total, 143 people developed diabetes at follow-up. The presence of a high FLI category was in all cases a significant independent risk factor for the development of diabetes. The inclusion of FLI categories in prediction models based on different conventional T2DM risk factors significantly increase the prediction power of the models when all the population was considered. According to our results, FLI might be considered an early indicator of T2DM development even under normoglycemic condition. The data also suggest that FLI could provide additional information for the prediction of T2DM in models based on conventional risk factors.
- Published
- 2021
15. Incidence and regression of metabolic syndrome in a representative sample of the Spanish population: results of the cohort di@bet
- Author
-
Universitat Rovira i Virgili, Cuesta M; Fuentes M; Rubio M; Bordiu E; Barabash A; Garcia de la Torre N; Rojo-Martinez G; Valdes S; Soriguer F; Vendrell JJ; Urrutia IM; Ortega E; Montanya E; Menendez E; Lago-Sampedro A; Gomis R; Goday A; Castell C; Badia-Guillen R; Girbés J; Gaztambide S; Franch-Nadal J; Delgado Álvarez E; Chaves FJ; Castano L; Calle-Pascual AL, Universitat Rovira i Virgili, and Cuesta M; Fuentes M; Rubio M; Bordiu E; Barabash A; Garcia de la Torre N; Rojo-Martinez G; Valdes S; Soriguer F; Vendrell JJ; Urrutia IM; Ortega E; Montanya E; Menendez E; Lago-Sampedro A; Gomis R; Goday A; Castell C; Badia-Guillen R; Girbés J; Gaztambide S; Franch-Nadal J; Delgado Álvarez E; Chaves FJ; Castano L; Calle-Pascual AL
- Abstract
Introduction Metabolic syndrome (MetS) is an important predictor of cardiovascular mortality. Identification of occurrence and regression trends of MetS could permit elaboration of preventive strategies with new targets. The objective of this study was to analyze the occurrence and regression rates of MetS and its associated factors in the representative cohort of Spain of the di@bet.es study. Research design and methods The di@bet.es study is a prospective cohort where 5072 people representative of the Spanish population over 18 years of age were randomly selected between 2009 and 2010. Follow-up was a median of 7.5 (IQR 7.2-7.9) years, with 2408 (47%) participating subjects. A total of 1881 (78%) subjects had all the pertinent data available and were included in this study. Results Of the 1146 subjects without baseline criteria for MetS, 294 (25.7%) developed MetS during follow-up, while of the 735 patients with prior MetS, 148 (20.1%) presented regression. Adjusted MetS incidence per 1000 person-years was 38 (95% CI 32 to 44), while regression incidence was 36 (95% CI 31 to 41). Regression rate was independently higher than incidence rate in the following: women, subjects aged 18-45, university-degree holders, patients without central obesity, without hypertension, as well as those with body mass index of <25 kg/m(2). Lower progression and higher regression rates were observed with an adapted 14-point Mediterranean Diet adherence screener questionnaire score of >11 in both groups and with >500 and >2000 MET-min/week of physical activity, respectively. Conclusions This study provides MetS incidence and regression rates, and identifies the target population for intervention strategies in Spain and possibly in other countries.
- Published
- 2020
16. Healthy dietary pattern and their corresponding gut microbiota profile are linked to a lower risk of type 2 diabetes, independent of the presence of obesity
- Author
-
Díaz-Rizzolo, D.A., primary, Kostov, B., additional, López-Siles, M., additional, Serra, A., additional, Colungo, C., additional, González-de-Paz, L., additional, Martinez-Medina, M., additional, Sisó-Almirall, A., additional, and Gomis, R., additional
- Published
- 2020
- Full Text
- View/download PDF
17. The Mitochondria-Targeted Antioxidant MitoQ Modulates Mitochondrial Function and Endoplasmic Reticulum Stress in Pancreatic ß Cells Exposed to Hyperglycaemia
- Author
-
Escribano-Lopez I, Bañuls C, Diaz-Morales N, Iannantuoni F, Rovira-Llopis S, Gomis R, Rocha M, Hernandez-Mijares A, Murphy MP, and Victor VM
- Subjects
ER stress, MitoQ, Mitochondrial dysfunction, Oxidative stress, Pancreatic ß cells, Type 2 Diabetes - Abstract
Mitochondria-targeted antioxidants such as mitoquinone (MitoQ) have demonstrated protective effects against oxidative damage in several diseases. The increase in reactive oxygen species (ROS) production during glucose metabolism in ß cells can be exacerbated under hyperglycaemic conditions such as type 2 diabetes (T2D), thus contributing to ß cell function impairment. In the present work, we aimed to evaluate the effect of MitoQ on insulin secretion, oxidative stress, endoplasmic reticulum (ER) stress and nuclear factor kappa B (NF?B) signalling in a pancreatic ß cell line under normoglycaemic (NG, 11.1 mM glucose), hyperglycaemic (HG, 25 mM glucose) and lipidic (palmitic acid (PA), 0.5mM) conditions.
- Published
- 2019
18. Spanish validation of Game Addiction Scale for Adolescents (GASA)
- Author
-
Lloret Irles D, Morell Gomis R, Marzo Campos JC, and TIRADO S
- Subjects
Computer-game ,Addiction ,Adolescence - Abstract
Objective: The aim of this study is to adapt and validate the Game Addiction Scale for Adolescents (GASA) to the Spanish youth population. Design: Cultural adaptation and validation study. Setting: Secondary Education centres. Participants: Two independent studies were conducted on a group of 466 young people with a mean age of 15.27 years (13-18, SD: 1.83) and 48.7% female and on another group of 566, with a mean age of 21.24 years (19-26; SD: 1.86) 44.1% female. Measurements: Addiction to video games (GASA); Game behavior (Game habits usage questionnaire), Impulsiveness (Plutchik Impulsiveness Scale) and Group Pressure (Ad hoc questionnaire). Results: The Spanish version of GASA has shown good reliability and true to the original scale factor structure. As regards criterion validity, GASA scores are significantly different according to four criteria related to problem gambling: Game intensity and frequency, impulsiveness, and peer pressure. Conclusions: The results show that the adapted version GASA is adequate and a valid tool for assessing problematic gaming behaviour. (C) 2017 Elsevier Espana, S.L.U.
- Published
- 2018
19. Abstract P1-17-01: Long term survival benefits of adjuvant zoledronic acid associated with maf status of primary tumor
- Author
-
Coleman, R, primary, Gregory, W, additional, Jean-Mairet, J, additional, Tercero, JC, additional, Torres-Martin, J, additional, and Gomis, R, additional
- Published
- 2019
- Full Text
- View/download PDF
20. Altered miR-17-5p expression pattern in response to chemotherapeutic drugs for metastatic colorectal cancer
- Author
-
Despotović, Jovana, Urosević, J., Gomis, R. R., Nikolić, Aleksandra, Despotović, Jovana, Urosević, J., Gomis, R. R., and Nikolić, Aleksandra
- Published
- 2018
21. Branched-Chain Amino Acid Database Integrated in MEDIPAD Software as a Tool for Nutritional Investigation of Mediterranean Populations
- Author
-
Universitat Rovira i Virgili, Haydar S; Paillot T; Fagot C; Cogne Y; Fountas A; Tutuncu Y; Vintila M; Tsatsoulis A; Chi PT; Garandeau P; Chetea D; Badiu C; Gheorghiu M; Ylli D; Lautier C; Jarec M; Monnier L; Normand C; Šarac J; Barakat A; Missoni S; Pugeat M; Poucheret P; Hanzu F; Gomis R; Macias JM; Litvinov S; Khusnutdinova E; Poiana C; Pasquali R; Lauro D; Sesti G; Trischitta V; Abdelhak S; Zenati A; Ylli A; Satman I; Kanninen T; Rinato Y; Grigorescu F, Universitat Rovira i Virgili, and Haydar S; Paillot T; Fagot C; Cogne Y; Fountas A; Tutuncu Y; Vintila M; Tsatsoulis A; Chi PT; Garandeau P; Chetea D; Badiu C; Gheorghiu M; Ylli D; Lautier C; Jarec M; Monnier L; Normand C; Šarac J; Barakat A; Missoni S; Pugeat M; Poucheret P; Hanzu F; Gomis R; Macias JM; Litvinov S; Khusnutdinova E; Poiana C; Pasquali R; Lauro D; Sesti G; Trischitta V; Abdelhak S; Zenati A; Ylli A; Satman I; Kanninen T; Rinato Y; Grigorescu F
- Abstract
Branched-chained amino acids (BCAA) are essential dietary components for humans and can act as potential biomarkers for diabetes development. To efficiently estimate dietary intake, we developed a BCAA database for 1331 food items found in the French Centre d'Information sur la Qualité des Aliments (CIQUAL) food table by compiling BCAA content from international tables, published measurements, or by food similarity as well as by calculating 267 items from Greek, Turkish, Romanian, and Moroccan mixed dishes. The database embedded in MEDIPAD software capable of registering 24 h of dietary recalls (24HDR) with clinical and genetic data was evaluated based on archived 24HDR of the Saint Pierre Institute (France) from 2957 subjects, which indicated a BCAA content up to 4.2 g/100 g of food and differences among normal weight and obese subjects across BCAA quartiles. We also evaluated the database of 119 interviews of Romanians, Turkish and Albanians in Greece (27⁻65 years) during the MEDIGENE program, which indicated mean BCAA intake of 13.84 and 12.91 g/day in males and females, respectively, comparable to other studies. The MEDIPAD is user-friendly, multilingual, and secure software and with the BCAA database is suitable for conducting nutritional assessment in the Mediterranean area with particular facilities for food administration.
- Published
- 2018
22. [Methodological aspects of integrated care pathways]
- Author
-
Gomis R, Mata Cases M, Mauricio Puente D, Artola Menendez S, Ena Munoz J, Mediavilla Bravo J, Miranda Fernandez-Santos C, Orozco Beltran D, Rodriguez Manas L, Sanchez Villalba C, and Martinez J
- Subjects
Diabetes Mellitus, Type 2 ,Delivery of Health Care, Integrated ,Spain ,Clinical protocols ,Type 2 diabetes mellitus ,Critical Pathways ,Humans ,Patient management ,Patient care ,Hypoglycaemia ,Critical pathways ,Hypoglycemia ,Case management - Abstract
An Integrated Healthcare Pathway (PAI) is a tool which has as its aim to increase the effectiveness of clinical performance through greater coordination and to ensure continuity of care. PAI places the patient as the central focus of the organisation of health services. It is defined as the set of activities carried out by the health care providers in order to increase the level of health and satisfaction of the population receiving services. The development of a PAI requires the analysis of the flow of activities, the inter-relationships between professionals and care teams, and patient expectations. The methodology for the development of a PAI is presented and discussed in this article, as well as the success factors for its definition and its effective implementation. It also explains, as an example, the recent PAI for Hypoglycaemia in patients with Type 2 Diabetes Mellitus developed by a multidisciplinary team and supported by several scientific societies. (C) 2017 SECA. Published by Elsevier Espana, S.L.U. All rights reserved.
- Published
- 2016
23. FoxA and LIPG endothelial lipase control the uptake of extracellular lipids for breast cancer growth
- Author
-
Slebe F, Rojo F, Vinaixa M, Garcia-Rocha M, Testoni G, Guiu M, Planet E, Samino S, Arenas E, Beltran A, Rovira A, Lluch A, Salvatella X, Yanes O, Albanell J, Guinovart J, and Gomis R
- Published
- 2016
24. Abstract P1-09-01: Impact of MAF gene amplification on disease recurrence and effects of adjuvant zoledronic acid in early breast cancer
- Author
-
Coleman, R, primary, Hall, A, additional, Bell, R, additional, Cameron, D, additional, Marshall, H, additional, Jean-Mairet, J, additional, Tercero, J, additional, Rojo, F, additional, Albanell, J, additional, and Gomis, R, additional
- Published
- 2017
- Full Text
- View/download PDF
25. Abstract P5-07-09: Stem cell-like transcriptional reprogramming in metastatic resistance
- Author
-
Pujana, MA, primary, Mateo, F, additional, Arenas, EJ, additional, and Gomis, R, additional
- Published
- 2017
- Full Text
- View/download PDF
26. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
- Author
-
Mateo, F, primary, Arenas, E J, additional, Aguilar, H, additional, Serra-Musach, J, additional, de Garibay, G Ruiz, additional, Boni, J, additional, Maicas, M, additional, Du, S, additional, Iorio, F, additional, Herranz-Ors, C, additional, Islam, A, additional, Prado, X, additional, Llorente, A, additional, Petit, A, additional, Vidal, A, additional, Català, I, additional, Soler, T, additional, Venturas, G, additional, Rojo-Sebastian, A, additional, Serra, H, additional, Cuadras, D, additional, Blanco, I, additional, Lozano, J, additional, Canals, F, additional, Sieuwerts, A M, additional, de Weerd, V, additional, Look, M P, additional, Puertas, S, additional, García, N, additional, Perkins, A S, additional, Bonifaci, N, additional, Skowron, M, additional, Gómez-Baldó, L, additional, Hernández, V, additional, Martínez-Aranda, A, additional, Martínez-Iniesta, M, additional, Serrat, X, additional, Cerón, J, additional, Brunet, J, additional, Barretina, M P, additional, Gil, M, additional, Falo, C, additional, Fernández, A, additional, Morilla, I, additional, Pernas, S, additional, Plà, M J, additional, Andreu, X, additional, Seguí, M A, additional, Ballester, R, additional, Castellà, E, additional, Nellist, M, additional, Morales, S, additional, Valls, J, additional, Velasco, A, additional, Matias-Guiu, X, additional, Figueras, A, additional, Sánchez-Mut, J V, additional, Sánchez-Céspedes, M, additional, Cordero, A, additional, Gómez-Miragaya, J, additional, Palomero, L, additional, Gómez, A, additional, Gajewski, T F, additional, Cohen, E E W, additional, Jesiotr, M, additional, Bodnar, L, additional, Quintela-Fandino, M, additional, López-Bigas, N, additional, Valdés-Mas, R, additional, Puente, X S, additional, Viñals, F, additional, Casanovas, O, additional, Graupera, M, additional, Hernández-Losa, J, additional, Ramón y Cajal, S, additional, García-Alonso, L, additional, Saez-Rodriguez, J, additional, Esteller, M, additional, Sierra, A, additional, Martín-Martín, N, additional, Matheu, A, additional, Carracedo, A, additional, González-Suárez, E, additional, Nanjundan, M, additional, Cortés, J, additional, Lázaro, C, additional, Odero, M D, additional, Martens, J W M, additional, Moreno-Bueno, G, additional, Barcellos-Hoff, M H, additional, Villanueva, A, additional, Gomis, R R, additional, and Pujana, M A, additional
- Published
- 2016
- Full Text
- View/download PDF
27. Low Physical Activity and Its Association with Diabetes and Other Cardiovascular Risk Factors: A Nationwide, Population-Based Study
- Author
-
Universitat Rovira i Virgili, Brugnara L, Murillo S, Novials A, Rojo-Martínez G, Soriguer F, Goday A, Calle-Pascual A, Castaño L, Gaztambide S, Valdés S, Franch J, Castell C, Vendrell J, Casamitjana R, Bosch-Comas A, Bordiú E, Carmena R, Catalá M, Delgado E, Girbés J, López-Alba A, Martínez-Larrad MT, Menéndez E, Mora-Peces I, Pascual-Manich G, Serrano-Ríos M, Gomis R, Ortega E, Universitat Rovira i Virgili, and Brugnara L, Murillo S, Novials A, Rojo-Martínez G, Soriguer F, Goday A, Calle-Pascual A, Castaño L, Gaztambide S, Valdés S, Franch J, Castell C, Vendrell J, Casamitjana R, Bosch-Comas A, Bordiú E, Carmena R, Catalá M, Delgado E, Girbés J, López-Alba A, Martínez-Larrad MT, Menéndez E, Mora-Peces I, Pascual-Manich G, Serrano-Ríos M, Gomis R, Ortega E
- Abstract
Low physical activity (PA), or sedentary lifestyle, is associated with the development of several chronic diseases. We aimed to investigate current prevalence of sedentariness and its association with diabetes and other cardiovascular risk factors. PA was evaluated in a population-based, cross-sectional, randomly sampled study conducted in 2009-2010 in Spain. International Physical Activity Questionnaire (SF-IPAQ) was used to assess PA. 4991 individuals (median age 50 years, 57% women) were studied. Prevalence of sedentariness was 32.3% for men and 39% for women (p < 0.0001). Sex differences were particularly notable (age*sex interaction, p = 0.0024) at early and older ages. Sedentary individuals had higher BMI (28 vs. 27 kg/m2) and obesity prevalence (37 vs. 26%). Low PA was present in 44, 43, and 38% of individuals with known diabetes (KDM), prediabetes/unknown-diabetes (PREDM/UKDM), and normal glucose regulation (p = 0.0014), respectively. No difference between KDM and PREDM/UKDM (p = 0.72) was found. Variables independently associated (p < 0.05) with sedentariness were age, sex, BMI, central obesity, Mediterranean diet adherence, smoking habit, HDL-cholesterol, triglycerides and dyslipidemia. Low PA is on the rise in Spain, especially among women. Sedentariness is associated with several cardiovascular risk factors and may be responsible for the increasing prevalence of obesity and diabetes in this country.
- Published
- 2016
28. Using lentivirally encoded miRnome library as a functional screen to identify miRNAs associated with invasion and metastasis in breast cancer
- Author
-
Goicoechea, I., primary, Larrea, E., additional, Manterola, L., additional, Gomis, R., additional, Schultz, I., additional, Schaapveld, R., additional, and Lawrie, C.H., additional
- Published
- 2016
- Full Text
- View/download PDF
29. Wnt9a deficiency discloses a repressive role of Tcf7l2 on endocrine differentiation in the embryonic pancreas
- Author
-
Pujadas, G., primary, Cervantes, S., additional, Tutusaus, A., additional, Ejarque, M., additional, Sanchez, L., additional, García, A., additional, Esteban, Y., additional, Fargas, L., additional, Alsina, B., additional, Hartmann, C., additional, Gomis, R., additional, and Gasa, R., additional
- Published
- 2016
- Full Text
- View/download PDF
30. Estimating Cardiovascular Risk in Spain by the European Guidelines on Cardiovascular Disease Prevention in Clinical Practice
- Author
-
Medicina i Cirurgia, Universitat Rovira i Virgili, Amor AJ, Masana L, Soriguer F, Goday A, Calle-Pascual A, Gaztambide S, Rojo-Martínez G, Valdés S, Gomis R, Ortega E, Di@bet.es study group, Medicina i Cirurgia, Universitat Rovira i Virgili, and Amor AJ, Masana L, Soriguer F, Goday A, Calle-Pascual A, Gaztambide S, Rojo-Martínez G, Valdés S, Gomis R, Ortega E, Di@bet.es study group
- Abstract
There are no nationwide, population-based studies in Spain assessing overall cardiovascular risk. We aimed to describe cardiovascular risk and achievement of treatment goals following the 2012 European Guidelines on cardiovascular disease prevention strategy. We also investigated clinical characteristics (non-classical risk factors) associated with moderate risk.Participants (n=2310, 58% women) aged 40 to 65 years from a national population-based study (Di@bet.es Study) were identified. First, a priori high/very-high risk individuals were identified. Next, total cardiovascular risk (Systematic Coronary Risk Evaluation equation including high-density lipoprotein cholesterol) was used to assess risk of a priori non-high risk individuals. Variables independently associated with moderate versus low-risk were investigated by multiple logistic regression analysis.Age-and-sex standardized (direct method) percentages of high/very-high, moderate, and low-risk were 22.8%, 43.5%, and 33.7%, respectively. Most men were at moderate (56.2%), while 55.4% of women were at low risk. Low-density lipoprotein cholesterol (< 70,<100, < 115 mg/dL) and blood pressure (<140/90 mmHg) goals for very-high, high and moderate risk were met in 15%, 26% and 46%, and 77%, 68% and 85% of the individuals, respectively. Body mass index, high triglycerides concentrations, diastolic blood pressure, and low Mediterranean diet adherence (in women) were independently associated with moderate (versus low) risk.Cardiovascular risk in Spain is mainly moderate in men and low in women. Achievement of treatment goals in high-risk individuals should be improved. The prevalence of non-classical cardiovascular risk factors is elevated in subjects at moderate risk, an important aspect to consider in a population-based
- Published
- 2015
31. The LUCA device - Laser and Ultrasound Co-Analyzer for Thyroid Nodules.
- Author
-
Cortese, L., Aranda, G., Buttafava, M., Contini, D., Mora, A. Dalla, de Fraguier, S., Dehghani, H., Garcia, E., Gomis, R., Hanzu, F., Torra, F. José, Krischak, K., Presti, G. Lo, Mora, M., Pifferi, A., Renna, M., Rosinski, B., Sekar, S. Konugolu Venkata, Squarcia, M., and Taroni, P.
- Published
- 2019
- Full Text
- View/download PDF
32. Pilot measurement of the microvascular blood flow of thyroid nodules by diffuse optics.
- Author
-
Presti, G. Lo, Aranda, G., Contini, D., Cortese, L., Mora, A. Dalla, de Fraguier, S., Gomis, R., Hanzu, F., Mora, M., Pifferi, A., Rosinski, B., Sekar, S. Konugolu Venkata, Squarcia, M., Taroni, P., Weigel, UM, and Durduran, T.
- Published
- 2019
- Full Text
- View/download PDF
33. Pilot measurement of the microvascular blood flow of thyroid nodules by diffuse optics
- Author
-
Dehghani, Hamid, Wabnitz, Heidrun, Lo Presti, G., Aranda, G., Contini, D., Cortese, L., Dalla Mora, A., de Fraguier, S., Gomis, R., Hanzu, F., Mora, M., Pifferi, A., Rosinski, B., Konugolu Venkata Sekar, S., Squarcia, M., Taroni, P., Weigel, UM, and Durduran, T.
- Published
- 2019
- Full Text
- View/download PDF
34. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition
- Author
-
Mateo, F, Arenas, E J, Aguilar, H, Serra-Musach, J, de Garibay, G Ruiz, Boni, J, Maicas, M, Du, S, Iorio, F, Herranz-Ors, C, Islam, A, Prado, X, Llorente, A, Petit, A, Vidal, A, Català, I, Soler, T, Venturas, G, Rojo-Sebastian, A, Serra, H, Cuadras, D, Blanco, I, Lozano, J, Canals, F, Sieuwerts, A M, de Weerd, V, Look, M P, Puertas, S, García, N, Perkins, A S, Bonifaci, N, Skowron, M, Gómez-Baldó, L, Hernández, V, Martínez-Aranda, A, Martínez-Iniesta, M, Serrat, X, Cerón, J, Brunet, J, Barretina, M P, Gil, M, Falo, C, Fernández, A, Morilla, I, Pernas, S, Plà, M J, Andreu, X, Seguí, M A, Ballester, R, Castellà, E, Nellist, M, Morales, S, Valls, J, Velasco, A, Matias-Guiu, X, Figueras, A, Sánchez-Mut, J V, Sánchez-Céspedes, M, Cordero, A, Gómez-Miragaya, J, Palomero, L, Gómez, A, Gajewski, T F, Cohen, E E W, Jesiotr, M, Bodnar, L, Quintela-Fandino, M, López-Bigas, N, Valdés-Mas, R, Puente, X S, Viñals, F, Casanovas, O, Graupera, M, Hernández-Losa, J, Ramón y Cajal, S, García-Alonso, L, Saez-Rodriguez, J, Esteller, M, Sierra, A, Martín-Martín, N, Matheu, A, Carracedo, A, González-Suárez, E, Nanjundan, M, Cortés, J, Lázaro, C, Odero, M D, Martens, J W M, Moreno-Bueno, G, Barcellos-Hoff, M H, Villanueva, A, Gomis, R R, and Pujana, M A
- Abstract
Inhibitors of the mechanistic target of rapamycin (mTOR) are currently used to treat advanced metastatic breast cancer. However, whether an aggressive phenotype is sustained through adaptation or resistance to mTOR inhibition remains unknown. Here, complementary studies in human tumors, cancer models and cell lines reveal transcriptional reprogramming that supports metastasis in response to mTOR inhibition. This cancer feature is driven by EVI1 and SOX9. EVI1 functionally cooperates with and positively regulates SOX9, and promotes the transcriptional upregulation of key mTOR pathway components (REHB and RAPTOR) and of lung metastasis mediators (FSCN1 and SPARC). The expression of EVI1 and SOX9 is associated with stem cell-like and metastasis signatures, and their depletion impairs the metastatic potential of breast cancer cells. These results establish the mechanistic link between resistance to mTOR inhibition and cancer metastatic potential, thus enhancing our understanding of mTOR targeting failure.
- Published
- 2017
- Full Text
- View/download PDF
35. Heart rate variability as an indicator of acid gastroesophageal reflux.
- Author
-
Murcia Clemente, L., Izquierdo Fos, I., Vázquez Gomis, R., López Yánez, A., and Valero Sánchez, M. Á.
- Published
- 2022
- Full Text
- View/download PDF
36. Study of factors associated with dietary trangressions in celiacs and analysis of ferritine levels according to adherence to a free gluten-free diet.
- Author
-
Vázquez-Gomis, R., Vázquez-Acebes, B., Juste-Ruiz, M., Izquierdo-Vázquez, A., and Izquierdo-Fos, I.
- Published
- 2022
- Full Text
- View/download PDF
37. CASE/CONTROL STUDY OF HNF1A GENETIC VARIANTS WITH THE METABOLIC SYNDROME IN THE TUNISIAN POPULATION.
- Author
-
DALLALI, H., HECHMI, M., ELOUEJ, S., JMEL, H., BEN HALIMA, Y., NAGARA, M., CHARGUI, M., KAMOUN, I., TURKI, Z., ABID, A., BAHRI, S., BAHLOUS, A., GOMIS, R., BARAKET, A., GRIGORESCU, F., NORMAND, C., JAMOUSSI, H., ABDELHAK, S., and KEFI, R.
- Subjects
METABOLIC syndrome ,OBESITY ,GLUCOSE ,INSULIN resistance ,HEPATOCYTE nuclear factors - Abstract
Background: Metabolic syndrome (MetS) is a complex disease involving a set of metabolic abnormalities ranging from obesity, glucose intolerance, hypertension to dyslipidemia and insulin resistance. Recent genome wide association studies (GWAS) have identified many genetic variants associated with MetS and/or its components located in several genetic loci including the hepatocyte nuclear factor 1 alpha (HNF1A) gene. However, the association of HNF1A variants with MetS in the Middle East and North Africa region is largely unknown. This study aims to examine their association with MetS and its components in the Tunisian population. Methods: A total of 594 Tunisian individuals (295 cases/299 controls) were genotyped for two variants (rs1169288 and rs2464196) located in the HNF1A gene using KASPar technology. Statistical association analyses were performed with the R software. Results: Our results showed no association between HNF1A variants and MetS in our studied Tunisian population. However, a significant association was observed between the variant rs2464196 and both waist circumference and HDL. Conclusion: Our findings exclude the implication of HNF1A gene variants (rs1169288 and rs2464196) in the susceptibility to MetS in our studied Tunisian population. The genotyping of a third variant located in HNF1A gene will allow us to perform a haplotypic analysis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
38. The LUCA device: laser and ultrasound co-analyzer for thyroid nodules
- Author
-
Dehghani, Hamid, Wabnitz, Heidrun, Cortese, L., Aranda, G., Buttafava, M., Contini, D., Dalla Mora, A., de Fraguier, S., Dehghani, H., García, E., Gomis, R., Hanzu, F., Josè Torra, F., Krischak, K., Lo Presti, G., Mora, M., Pifferi, A., Renna, M., Rosinski, B., Konugolu Venkata Sekar, S., Squarcia, M., Taroni, P., Tosi, A., Weigel, U. M., Wojtkiewicz, S., Zanoletti, M., Zolda, P., and Durduran, T.
- Published
- 2019
- Full Text
- View/download PDF
39. NUTRITION AND THE CLOCK GENE.
- Author
-
Figueroa, A. L. C., Hanzu, F., and Gomis, R.
- Subjects
- *
NUTRITION , *CLOCK genes , *GENETICS of circadian rhythms , *METABOLISM , *BIOLOGICAL rhythms , *OBESITY , *DIABETES - Abstract
A number of recent studies in animals and humans have linked energy regulation and the circadian clock at the molecular, physiological and behavioural levels, concluding that disruption of clock genes results in metabolic dysregulation. The search to understand the causes of obesity and diabetes and the development of new therapeutic strategies have mostly focused on caloric intake and energy balance. In this review, we present a global overview of the circadian clock as a critical interface between nutrition and homeostasis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
40. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes : a pilot randomized trial
- Author
-
Balfegó, Mariona, Canivell, S., Hanzu, Felicia A., Sala Vila, Aleix, Martínez Medina, Margarita, Murillo, Serafín, Mur, Teresa, Ruano, Elena G., Linares, Francisca, Porras, Nuria, Valladares, Silvia, Fontalba, Maria, Roura, Elena, Novials, Anna, Hernández, Cristina, Aranda, Gloria, Sisó Almirall, Antoni, Rojo Martínez, Gemma, Simó Canonge, Rafael, Gomis, Ramon, Universitat Autònoma de Barcelona, Universitat de Barcelona, [Balfegó,M, Hanzu,FA, Murillo,S, Ruano,EG, Linares,F, Porras,N, Valladares,S, Fontalba,M, Novials,A, Hernández,C, Rojo-Martínez,G, Simó,R, Gomis,R] CIBER in Diabetes and Associated Metabolic Disorders (CIBERDEM), Madrid, Spain. [Balfegó,M, Canivell,S, Gomis,R] Diabetesand Obesity Research Laboratory, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain. [Canivell,S, Sisó-Almirall,A] Les Corts Primary Health Care Center, Tranverse Group for Research in Primary Care, IDIBAPS, Barcelona, Spain. [Hanzu,FA, Novials,A: Aranda,G, Gomis,R] Department of Endocrinology and Nutrition, Hospital Clínic of Barcelona, Barcelona, Spain. [Sala-Vila,A] CIBER in Physiopathology of Obesity and Nutrition (CIBERobn), Barcelona, Spain. [Martínez-Medina,M] Laboratory of Molecular Microbiology, Biology Department, University of Girona, Girona, Spain. [Mur,T] Terrassa Sud Primary Health Care Center, Mútua de Terrassa, Terrassa, Barcelona, Spain. [Linares,F, Rojo-Martínez,G] Endocrinology and Nutrition Department, Hospital Carlos Haya, Biomedical Research Institute of Málaga (IBIMA), Málaga, Spain. [Valladares,S, Simó,R] Vall d’Hebrón Research Institute and Autonomous University of Barcelona, Barcelona, Spain. [Roura,E] Alicia Foundation, Barcelona, Spain. [Hanzu,FA, Sisó-Almirall,A, Gomis,R] University of Barcelona, Facultat de Medicina Barcelona, Spain. [Canivell,S] Centre Hospitalier Universitaire Vaudois 8CHUV), Departement de Endocrinologie, Lausanne, Switzerland., and This work was sponsored by funding from Catalunya-La Pedrera Foundation, the Government of Catalonia under the grant agreement 2014 SGR659 and the Ajut ACD Gonçal LLoveras i Valles 2014. Ciberdem is an initiative of the Instituto de Salud Carlos III.
- Subjects
Male ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Proyectos piloto ,Organisms::Bacteria::Proteobacteria::Gammaproteobacteria::Enterobacteriaceae::Escherichia::Escherichia coli [Medical Subject Headings] ,Gastroenterology ,Type 2 diabete ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,0302 clinical medicine ,Endocrinology ,Chemicals and Drugs::Lipids::Fatty Acids::Fatty Acids, Unsaturated::Fatty Acids, Omega-3 [Medical Subject Headings] ,Organisms::Eukaryota::Animals [Medical Subject Headings] ,Homeostasis ,Bacteroides ,Oily fish ,Non-insulin-dependent diabetes ,Organisms::Bacteria::Bacteroidetes::Bacteroidaceae::Prevotella [Medical Subject Headings] ,Ácidos grasos omega 3 ,Anatomy::Hemic and Immune Systems::Blood::Blood Cells::Erythrocytes::Erythrocyte Membrane [Medical Subject Headings] ,Diabetis ,Sardine ,Fatty Acids ,Fishes ,Humanos ,Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Fasting [Medical Subject Headings] ,Body Composition ,Dieta ,Adiponectin ,Terapia nutricional ,Enfermedades cardiovasculares ,Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Pancreatic Hormones::Insulins::Proinsulin::Insulin [Medical Subject Headings] ,Adiponectina ,Factores de riesgo ,medicine.medical_specialty ,Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Peptide Hormones::Adipokines::Adiponectin [Medical Subject Headings] ,Microbiota intestinal ,Resistencia a la insulina ,Grupos control ,03 medical and health sciences ,Sardines ,Humans ,Diseases::Cardiovascular Diseases [Medical Subject Headings] ,Biochemistry, medical ,030109 nutrition & dietetics ,Membrana eritrocítica ,Erythrocyte Membrane ,Diseases::Endocrine System Diseases::Diabetes Mellitus::Diabetes Mellitus, Type 2 [Medical Subject Headings] ,medicine.disease ,Organisms::Bacteria::Bacteroidetes::Bacteroidaceae::Bacteroides [Medical Subject Headings] ,Alimentació ,Pilot trial ,chemistry ,Diabetes Mellitus, Type 2 ,Glucosa ,Animales ,Biomarkers ,0301 basic medicine ,Clinical Biochemistry ,Prevotella ,Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose [Medical Subject Headings] ,Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Drug Resistance::Insulin Resistance [Medical Subject Headings] ,Pilot Projects ,Type 2 diabetes ,Hemoglobina A glicosilada ,Diabetis no-insulinodependent ,chemistry.chemical_compound ,Clinical trials ,Insulina ,Health Care::Health Care Economics and Organizations::Policy::Social Control Policies::Public Policy::Health Policy::Nutrition Policy [Medical Subject Headings] ,Adiponectin/blood ,Animals ,Biomarkers/blood ,Body Composition/drug effects ,Diabetes Mellitus, Type 2/diet therapy ,Diabetes Mellitus, Type 2/microbiology ,Erythrocyte Membrane/chemistry ,Erythrocyte Membrane/drug effects ,Fatty Acids/analysis ,Fatty Acids/blood ,Fatty Acids, Omega-3/blood ,Female ,Fish Products ,Gastrointestinal Microbiome ,Inflammation/blood ,Middle Aged ,Nutrition therapy ,Medical nutrition therapy ,Política nutricional ,Diabetes ,Organisms::Bacteria::Bacteroidetes [Medical Subject Headings] ,Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Causality::Risk Factors [Medical Subject Headings] ,Organisms::Bacteria::Firmicutes [Medical Subject Headings] ,Phenomena and Processes::Biological Phenomena::Ecological and Environmental Phenomena::Environment::Ecosystem::Biodiversity::Biota::Microbiota::Gastrointestinal Microbiome [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Methods::Research Design::Control Groups [Medical Subject Headings] ,Firmicutes ,030209 endocrinology & metabolism ,Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet [Medical Subject Headings] ,Ayuno ,Insulin resistance ,Chemicals and Drugs::Carbohydrates::Glycosides::Hemoglobin A, Glycosylated [Medical Subject Headings] ,Diabetes mellitus ,Internal medicine ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy [Medical Subject Headings] ,Fatty Acids, Omega-3 ,Escherichia coli ,medicine ,Gastrointestinal microbiome ,Inflammation ,Bacteroidetes ,business.industry ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Evaluation Studies as Topic::Pilot Projects [Medical Subject Headings] ,Insulin ,Research ,Biochemistry (medical) ,Diet ,Diabetes mellitus tipo II ,Glycated hemoglobin ,business ,Phenomena and Processes::Physiological Phenomena::Physiological Processes::Homeostasis [Medical Subject Headings] ,Glucosa sanguínea ,Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose::Blood Glucose [Medical Subject Headings] ,Assaigs clínics - Abstract
Background Nutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number of human studies examining the effects of oily fish on different cardiovascular risk factors, little research on this topic is available in patients with type 2 diabetes. The aims of this pilot study were to investigate the effects of a sardine-enriched diet on metabolic control, adiponectin, inflammatory markers, erythrocyte membrane fatty acid (EMFA) composition, and gut microbiota in drug-naïve patients with type 2 diabetes. Methods 35 drug-naïve patients with type 2 diabetes were randomized to follow either a type 2 diabetes standard diet (control group: CG), or a standard diet enriched with 100 g of sardines 5 days a week (sardine group: SG) for 6 months. Anthropometric, dietary information, fasting glycated hemoglobin, glucose, insulin, adiponectin, inflammatory markers, EMFA and specific bacterial strains were determined before and after intervention. Results There were no significant differences in glycemic control between groups at the end of the study. Both groups decreased plasma insulin (SG: −35.3 %, P = 0.01, CG: −22.6 %, P = 0.02) and homeostasis model of assessment - insulin resistance (HOMA-IR) (SG: −39.2 %, P = 0.007, CG: −21.8 %, P = 0.04) at 6-months from baseline. However only SG increased adiponectin in plasma compared to baseline level (+40.7 %, P = 0.04). The omega-3 index increased 2.6 % in the SG compared to 0.6 % in the CG (P = 0.001). Both dietary interventions decreased phylum Firmicutes (SG and CG: P = 0.04) and increased E. coli concentrations (SG: P = 0.01, CG: P = 0.03) at the end of the study from baseline, whereas SG decreased Firmicutes/Bacteroidetes ratio (P = 0.04) and increased Bacteroides-Prevotella (P = 0.004) compared to baseline. Conclusions Although enriching diet with 100 g of sardines 5 days a week during 6 months to a type 2 diabetes standard diet seems to have neutral effects on glycemic control in drug-naïve patients with type 2 diabetes, this nutritional intervention could have beneficial effects on cardiovascular risk. Furthermore, both dietary interventions decreased HOMA-IR and altered gut microbiota composition of drug-naïve patients with type 2 diabetes. Trial registration Trial number and name of the registry: NCT02294526, ClinicalTrials.gov Electronic supplementary material The online version of this article (doi:10.1186/s12944-016-0245-0) contains supplementary material, which is available to authorized users.
- Published
- 2016
41. Low physical activity and its association with diabetes and other cardiovascular risk factors: a nationwide, population-based study
- Author
-
Sonia Gaztambide, Edelmiro Menéndez, Gemma Pascual-Manich, Federico Soriguer, Anna Bosch-Comas, Rafael Carmena, Ramon Gomis, Inmaculada Mora-Peces, Albert Goday, Miguel Catalá, Laura Brugnara, María Teresa Martínez-Larrad, Anna Novials, Joan Vendrell, Emilio Ortega, Josep Franch, Alfonso L. Calle-Pascual, Serafín Murillo, Juan Girbés, Roser Casamitjana, Alfonso López-Alba, Manuel Serrano-Ríos, Elena Bordiú, Gemma Rojo-Martínez, Luis Castaño, Sergio Valdés, Elías Delgado, Conxa Castell, Universitat de Barcelona, [Brugnara,L, Murillo,S, Novials,A, Rojo-Martínez,G, Soriguer,F, Castaño,L, Gaztambide,S, Valdés,S, Vendrell,J, Casamitjana,R, Boch-Comas,A, Carmena,R, Catalá,M, Martínez-Larrad,MT, Pascual-Manich,G, Serrano-Rios,M, Gomis,R] CIBERDEM—Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders, Madrid, Spain. [Brugnara,L, Bosch-Comas,A, Gomis,R] IDIBAPS—August Pi i Sunyer Biomedical Research Institute / Hospital Clínic de Barcelona, Barcelona, Spain. [Rojo-Martínez,G, Valdés,S] Hospital Universitario Carlos Haya, Department of Endocrinology and Nutrition, Málaga, Spain. [Goday,A] Hospital del Mar, Department of Endocrinology and Nutrition, Barcelona, Spain. [Calle-Pascual,A, Bordiú,E] Hospital Universitario San Carlos, Madrid, Spain. [Gaztambide,S] Hospital Universitario de Cruces, UPV-EHU, Diabetes Research Group, Baracaldo, Spain. [Franch,J] EAP Raval Sud, Institut Català de la Salut, Red GEDAPS, IDIAP, Barcelona, Spain. [Castell,C] Public Health Division, Autonomous Government of Catalonia, Barcelona, Spain. [Vendrell,J] Department of Endocrinology and Nutrition, Hospital Universitario Joan XXIII, Tarragona, Spain. [Carmena,R, Catalá,M] Department of Medicine and Endocrinology, Hospital Clínico Universitario de Valencia, Valencia, Spain. [Delgado,E, Menéndez,E] Department of Endocrinology and Nutrition, Hospital Universitario Central de Asturias, Facultad de Medicina y Ciencias de la Salud, Universidad de Oviedo, Oviedo, Spain. [Gilbés,J] Hospital Arnau de Vilanova, Valencia, Spain. [López-Alba,A] Fundación Hospital de Jove, Gijón, Spain. [Serrano-Ríos,M] Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Madrid, Spain. [Mora-Peces,I] Canarian Health Service, San Cristóbal de la Laguna, Tenerife, Spain. [Martínez-Larraz,MT, Ortega,E] CIBEROBN - Spanish Biomedical Research Centre in Physiopathology of Obesity. [Ortega,E] Department of Endocrinology and Nutrition, ICMDM, Hospital Clinic Barcelona., This work was supported by the Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM, ISCIII Ministerio de Ciencia e Innovación), Ministerio de Sanidad y Consumo and the Spanish Diabetes Society (SED)., [Brugnara, Laura] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Murillo, Serafin] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Novials, Anna] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Rojo-Martinez, Gemma] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Soriguer, Federico] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Castano, Luis] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Gaztambide, Sonia] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Valdes, Sergio] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Vendrell, Joan] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Casamitjana, Roser] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Bosch-Comas, Anna] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Carmena, Rafael] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Catala, Miguel] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Teresa Martinez-Larrad, Maria] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Pascual-Manich, Gemma] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Serrano-Rios, Manuel] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Gomis, Ramon] CIBERDEM Spanish Biomed Res Ctr Diabet & Associat, Madrid, Spain, [Brugnara, Laura] Hosp Clin Barcelona, IDIBAPS August Pi & Sunyer Biomed Res Inst, Barcelona, Spain, [Murillo, Serafin] Hosp Clin Barcelona, IDIBAPS August Pi & Sunyer Biomed Res Inst, Barcelona, Spain, [Novials, Anna] Hosp Clin Barcelona, IDIBAPS August Pi & Sunyer Biomed Res Inst, Barcelona, Spain, [Casamitjana, Roser] Hosp Clin Barcelona, IDIBAPS August Pi & Sunyer Biomed Res Inst, Barcelona, Spain, [Bosch-Comas, Anna] Hosp Clin Barcelona, IDIBAPS August Pi & Sunyer Biomed Res Inst, Barcelona, Spain, [Pascual-Manich, Gemma] Hosp Clin Barcelona, IDIBAPS August Pi & Sunyer Biomed Res Inst, Barcelona, Spain, [Gomis, Ramon] Hosp Clin Barcelona, IDIBAPS August Pi & Sunyer Biomed Res Inst, Barcelona, Spain, [Rojo-Martinez, Gemma] Hosp Univ Carlos Haya, Dept Endocrinol & Nutr, Malaga, Spain, [Soriguer, Federico] Hosp Univ Carlos Haya, Dept Endocrinol & Nutr, Malaga, Spain, [Valdes, Sergio] Hosp Univ Carlos Haya, Dept Endocrinol & Nutr, Malaga, Spain, [Goday, Albert] Hosp Mar, Dept Endocrinol & Nutr, Barcelona, Spain, [Calle-Pascual, Alfonso] Hosp Univ San Carlos, Madrid, Spain, [Bordiu, Elena] Hosp Univ San Carlos, Madrid, Spain, [Castano, Luis] Univ Basque Country, Hosp Univ Cruces, Diabet Res Grp, Baracaldo, Spain, [Gaztambide, Sonia] Univ Basque Country, Hosp Univ Cruces, Diabet Res Grp, Baracaldo, Spain, [Franch, Josep] IDIAP, Red GEDAPS, Inst Catala Salut, EAP Raval Sud, Barcelona, Spain, [Castell, Conxa] Autonomous Govt Catalonia, Publ Hlth Div, Barcelona, Spain, [Vendrell, Joan] Hosp Univ Joan XXIII, Dept Endocrinol & Nutr, Tarragona, Spain, [Carmena, Rafael] Hosp Clin Univ Valencia, Dept Med & Endocrinol, Valencia, Spain, [Catala, Miguel] Hosp Clin Univ Valencia, Dept Med & Endocrinol, Valencia, Spain, [Delgado, Elias] Univ Oviedo, Hosp Univ Cent Asturias, Fac Med & Ciencias Salud, Dept Endocrinol & Nutr, Oviedo, Spain, [Menendez, Edelmiro] Univ Oviedo, Hosp Univ Cent Asturias, Fac Med & Ciencias Salud, Dept Endocrinol & Nutr, Oviedo, Spain, [Girbes, Juan] Hosp Arnau Vilanova, Valencia, Spain, [Lopez-Alba, Alfonso] Fdn Hosp Jove, Gijon, Spain, [Serrano-Rios, Manuel] Hosp Clin San Carlos IdISSC, Inst Invest Sanitaria, Madrid, Spain, [Mora-Peces, Inmaculada] Canarian Hlth Serv, Tenerife, Spain, [Teresa Martinez-Larrad, Maria] CIBEROBN Spanish Biomed Res Ctr Physiopathol Obes, Pamplona, Spain, [Ortega, Emilio] CIBEROBN Spanish Biomed Res Ctr Physiopathol Obes, Pamplona, Spain, [Ortega, Emilio] Hosp Clin Barcelona, ICMDM, Dept Endocrinol & Nutr, Barcelona, Spain, Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM, ISCIII Ministerio de Ciencia e Innovacion), Ministerio de Sanidad y Consumo, and Spanish Diabetes Society (SED)
- Subjects
Questionnaires ,Male ,Dislipidemias ,Cross-sectional study ,Estudios transversales ,España ,Obesidad ,Índice de masa corporal ,Biochemistry ,Body Mass Index ,0302 clinical medicine ,Endocrinology ,Phenomena and Processes::Musculoskeletal and Neural Physiological Phenomena::Musculoskeletal Physiological Phenomena::Musculoskeletal Physiological Processes::Movement::Motor Activity [Medical Subject Headings] ,Public and Occupational Health ,lcsh:Science ,Phenomena and Processes::Physiological Phenomena::Nutritional Physiological Phenomena::Diet::Diet, Mediterranean [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Vital Statistics::Morbidity::Prevalence [Medical Subject Headings] ,Chemicals and Drugs::Lipids::Glycerides::Triglycerides [Medical Subject Headings] ,Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings] ,Aged, 80 and over ,Diabetis ,Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Lipid Metabolism Disorders::Dyslipidemias [Medical Subject Headings] ,Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity::Obesity, Abdominal [Medical Subject Headings] ,Cardiovascular Diseases ,Obesitat ,Enfermedades cardiovasculares ,Factores de riesgo ,medicine.medical_specialty ,Endocrine Disorders ,Chemicals and Drugs::Lipids::Lipoproteins::Lipoproteins, HDL::Cholesterol, HDL [Medical Subject Headings] ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Behavior::Habits::Smoking [Medical Subject Headings] ,Qüestionaris ,Triglicéridos ,Exercici -- Aspectes sanitaris ,03 medical and health sciences ,Diabetes Mellitus ,Humans ,Diseases::Cardiovascular Diseases [Medical Subject Headings] ,Exercise ,Aged ,Survey Research ,Malalties cardiovasculars ,Prevention ,lcsh:R ,Enfermedad crónica ,Biology and Life Sciences ,Physical Activity ,Insulin-resistance ,medicine.disease ,Actividad motora ,Obesity ,Lipid metabolism ,Cross-Sectional Studies ,Dyslipidemia ,Adherence ,Glucosa ,lcsh:Q ,Body mass index ,Demography ,Psychiatry and Psychology::Behavior and Behavior Mechanisms::Psychology, Social::Life Style::Sedentary Lifestyle [Medical Subject Headings] ,Physiology ,Physical fitness ,Sistema cardiovascular -- Malalties ,Chemicals and Drugs::Carbohydrates::Monosaccharides::Hexoses::Glucose [Medical Subject Headings] ,lcsh:Medicine ,Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Overweight::Obesity [Medical Subject Headings] ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings] ,Obesidad abdominal ,Geographical Locations ,Glucose Metabolism ,Risk Factors ,Hábito de fumar ,Medicine and Health Sciences ,Prevalence ,030212 general & internal medicine ,Prediabetes ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [Medical Subject Headings] ,Multidisciplinary ,Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Chronic Disease [Medical Subject Headings] ,Diabetes ,Middle Aged ,Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings] ,Europe ,Encuestas y cuestionarios ,Physiological Parameters ,Research Design ,Carbohydrate Metabolism ,Female ,Research Article ,Adult ,Adolescent ,030209 endocrinology & metabolism ,Vida sedentaria ,Research and Analysis Methods ,HDL-colesterol ,Young Adult ,Sex Factors ,Diabetes mellitus ,medicine ,Adults ,Espanya ,Diseases::Endocrine System Diseases::Diabetes Mellitus::Prediabetic State [Medical Subject Headings] ,Sedentary lifestyle ,business.industry ,Estado prediabético ,Body Weight ,Dieta mediterránea ,Metabolisme dels lípids ,Diet ,Metabolism ,Spain ,Metabolic Disorders ,People and Places ,Physical therapy ,Sedentary Behavior ,business ,Prevalencia ,Condició física - Abstract
Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM; ISCIII Ministerio de Ciencia e Innovacion); Ministerio de Sanidad y Consumo; Spanish Diabetes Society (SED), Brugnara, L., Murillo, S., Novials, A., Rojo-Martínez, G., Soriguer, F., Goday, A., Calle-Pascual, A., Castaño, L., Gaztambide, S., Valdés, S., Franch, J., Castell, C., Vendrell, J., Casamitjana, R., Bosch-Comas, A., Bordiú, E., Carmena, R., Catalá, M., Delgado, E., Girbés, J., López-Alba, A., Martínez-Larrad, M.T., Menéndez, E., Mora-Peces, I., Pascual-Manich, G., Serrano-Ríos, M., Gomis, R., Ortega, E.
- Published
- 2016
42. 232 - Using lentivirally encoded miRnome library as a functional screen to identify miRNAs associated with invasion and metastasis in breast cancer.
- Author
-
Goicoechea, I., Larrea, E., Manterola, L., Gomis, R., Schultz, I., Schaapveld, R., and Lawrie, C.H.
- Published
- 2016
- Full Text
- View/download PDF
43. Direct reprogramming of human fibroblasts into insulin-producing cells using transcription factors.
- Author
-
Fontcuberta-PiSunyer M, García-Alamán A, Prades È, Téllez N, Alves-Figueiredo H, Ramos-Rodríguez M, Enrich C, Fernandez-Ruiz R, Cervantes S, Clua L, Ramón-Azcón J, Broca C, Wojtusciszyn A, Montserrat N, Pasquali L, Novials A, Servitja JM, Vidal J, Gomis R, and Gasa R
- Subjects
- Humans, Gene Expression Regulation, Cell Differentiation physiology, Fibroblasts metabolism, Transcription Factors genetics, Transcription Factors metabolism, Insulin metabolism
- Abstract
Direct lineage reprogramming of one somatic cell into another without transitioning through a progenitor stage has emerged as a strategy to generate clinically relevant cell types. One cell type of interest is the pancreatic insulin-producing β cell whose loss and/or dysfunction leads to diabetes. To date it has been possible to create β-like cells from related endodermal cell types by forcing the expression of developmental transcription factors, but not from more distant cell lineages like fibroblasts. In light of the therapeutic benefits of choosing an accessible cell type as the cell of origin, in this study we set out to analyze the feasibility of transforming human skin fibroblasts into β-like cells. We describe how the timed-introduction of five developmental transcription factors (Neurog3, Pdx1, MafA, Pax4, and Nkx2-2) promotes conversion of fibroblasts toward a β-cell fate. Reprogrammed cells exhibit β-cell features including β-cell gene expression and glucose-responsive intracellular calcium mobilization. Moreover, reprogrammed cells display glucose-induced insulin secretion in vitro and in vivo. This work provides proof-of-concept of the capacity to make insulin-producing cells from human fibroblasts via transcription factor-mediated direct reprogramming., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
44. Remission of obesity and insulin resistance is not sufficient to restore mitochondrial homeostasis in visceral adipose tissue.
- Author
-
Gonzalez-Franquesa A, Gama-Perez P, Kulis M, Szczepanowska K, Dahdah N, Moreno-Gomez S, Latorre-Pellicer A, Fernández-Ruiz R, Aguilar-Mogas A, Hoffman A, Monelli E, Samino S, Miró-Blanch J, Oemer G, Duran X, Sanchez-Rebordelo E, Schneeberger M, Obach M, Montane J, Castellano G, Chapaprieta V, Sun W, Navarro L, Prieto I, Castaño C, Novials A, Gomis R, Monsalve M, Claret M, Graupera M, Soria G, Wolfrum C, Vendrell J, Fernández-Veledo S, Enríquez JA, Carracedo A, Perales JC, Nogueiras R, Herrero L, Trifunovic A, Keller MA, Yanes O, Sales-Pardo M, Guimerà R, Blüher M, Martín-Subero JI, and Garcia-Roves PM
- Subjects
- Adipose Tissue metabolism, Animals, Homeostasis, Intra-Abdominal Fat metabolism, Mice, Obesity genetics, Obesity metabolism, Proteomics, Insulin Resistance
- Abstract
Metabolic plasticity is the ability of a biological system to adapt its metabolic phenotype to different environmental stressors. We used a whole-body and tissue-specific phenotypic, functional, proteomic, metabolomic and transcriptomic approach to systematically assess metabolic plasticity in diet-induced obese mice after a combined nutritional and exercise intervention. Although most obesity and overnutrition-related pathological features were successfully reverted, we observed a high degree of metabolic dysfunction in visceral white adipose tissue, characterized by abnormal mitochondrial morphology and functionality. Despite two sequential therapeutic interventions and an apparent global healthy phenotype, obesity triggered a cascade of events in visceral adipose tissue progressing from mitochondrial metabolic and proteostatic alterations to widespread cellular stress, which compromises its biosynthetic and recycling capacity. In humans, weight loss after bariatric surgery showed a transcriptional signature in visceral adipose tissue similar to our mouse model of obesity reversion. Overall, our data indicate that obesity prompts a lasting metabolic fingerprint that leads to a progressive breakdown of metabolic plasticity in visceral adipose tissue., (Copyright © 2022 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
45. Glycaemia Fluctuations Improvement in Old-Age Prediabetic Subjects Consuming a Quinoa-Based Diet: A Pilot Study.
- Author
-
Díaz-Rizzolo DA, Acar-Denizli N, Kostov B, Roura E, Sisó-Almirall A, Delicado P, and Gomis R
- Subjects
- Blood Glucose metabolism, Cross-Over Studies, Diet, Humans, Pilot Projects, Chenopodium quinoa, Diabetes Mellitus, Type 2 prevention & control, Prediabetic State
- Abstract
This study aimed to observe if quinoa could produce a benefit on postprandial glycemia that would result in less progression to type 2 diabetes (T2D). A cross-over design pilot clinical study with a nutritional intervention for 8 weeks was performed: 4 weeks on a regular diet (RD) and 4 weeks on a quinoa diet (QD). Nine subjects aged ≥65 years with prediabetes were monitored during the first 4 weeks of RD with daily dietary records and FreeStyle Libre®. Subsequently, participants started the QD, where quinoa and 100% quinoa-based products replaced foods rich in complex carbohydrates that they had consumed in the first 4 weeks of RD. The glycemic measurements recorded by the sensors were considered as functions of time, and the effects of nutrients consumed at the intended time period were analyzed by means of a function-on-scalar regression (fosr) model. With QD participants, decreased body weight (−1.6 kg, p = 0.008), BMI (−0.6 kg/m2p = 0.004) and waist circumference (−1.5 cm, p = 0.015) were observed. Nutrients intake changed during QD, namely, decreased carbohydrates (p = 0.004) and increased lipids (p = 0.004) and some amino acids (p < 0.05). The fosr model showed a reduction in postprandial glycemia in QD despite intrapersonal differences thanks to the joint action of different nutrients and the suppression of others consumed on a regular diet. We conclude that in an old age and high T2D-risk population, a diet rich in quinoa reduces postprandial glycemia and could be a promising T2D-preventive strategy.
- Published
- 2022
- Full Text
- View/download PDF
46. Our journal is 65 years-old (I): A look back at the past.
- Author
-
Corcoy R, Lucas A, Gomis R, Mauricio D, Wägner A, Jiménez A, Fajardo C, Ballesteros M, Gimeno JA, and Zafon C
- Published
- 2022
- Full Text
- View/download PDF
47. Low Percentage of Vegetable Fat in Red Blood Cells Is Associated with Worse Glucose Metabolism and Incidence of Type 2 Diabetes.
- Author
-
Chiva-Blanch G, Giró O, Cofán M, Calle-Pascual AL, Delgado E, Gomis R, Jiménez A, Franch-Nadal J, Rojo Martínez G, and Ortega E
- Subjects
- Adult, Docosahexaenoic Acids, Eicosapentaenoic Acid, Erythrocytes metabolism, Fatty Acids, Female, Glucose analysis, Humans, Incidence, Linoleic Acid, Male, Middle Aged, Vegetables metabolism, alpha-Linolenic Acid, Diabetes Mellitus, Type 2 epidemiology, Diabetes Mellitus, Type 2 etiology, Fatty Acids, Omega-3 analysis
- Abstract
The identification of nutritional patterns associated with the development of type 2 diabetes (T2D) might help lead the way to a more efficient and personalized nutritional intervention. Our study is aimed at evaluating the association between fatty acids (FA) in red blood cell (RBC) membranes, as a quantitative biomarker of regular dietary fat intake, and incident type 2 diabetes in a Spanish population. We included 1032 adult Spaniards (57% women, age 49 ± 15 years, 18% prediabetes), without diabetes at study entry, from the Di@bet.es cohort. Incident diabetes was diagnosed at the end of the study follow-up. The FA percentage in RBC was determined at baseline by gas chromatography. Participants were followed on average 7.5 ± 0.6 years. Lower percentages of linoleic acid (LA), α-linolenic (ALA), and eicosapentaenoic acid (EPA), and higher percentages of docosahexaenoic acid (DHA) in RBC membranes were associated, independently of classical risk factors, with worse glucose metabolism at the end of the study follow-up. In addition, higher percentages of ALA and EPA, and moderate percentages of DHA, were associated with lower risk of diabetes. No significant associations were found for LA and diabetes risk. Dietary patterns rich in vegetables are independently associated with lower risk of both deterioration of glucose regulation and incident diabetes, and should be reinforced for the prevention of diabetes.
- Published
- 2022
- Full Text
- View/download PDF
48. Gsα-dependent signaling is required for postnatal establishment of a functional β-cell mass.
- Author
-
Serra-Navarro B, Fernandez-Ruiz R, García-Alamán A, Pradas-Juni M, Fernandez-Rebollo E, Esteban Y, Mir-Coll J, Mathieu J, Dalle S, Hahn M, Ahlgren U, Weinstein LS, Vidal J, Gomis R, and Gasa R
- Subjects
- Animals, GTP-Binding Protein alpha Subunits, Gs deficiency, Mice, Knockout, Mice, Transgenic, Signal Transduction, Mice, GTP-Binding Protein alpha Subunits, Gs metabolism, Insulin-Secreting Cells metabolism
- Abstract
Objective: Early postnatal life is a critical period for the establishment of the functional β-cell mass that will sustain whole-body glucose homeostasis during the lifetime. β cells are formed from progenitors during embryonic development but undergo significant expansion in quantity and attain functional maturity after birth. The signals and pathways involved in these processes are not fully elucidated. Cyclic adenosine monophosphate (cAMP) is an intracellular signaling molecule that is known to regulate insulin secretion, gene expression, proliferation, and survival of adult β cells. The heterotrimeric G protein Gs stimulates the cAMP-dependent pathway by activating adenylyl cyclase. In this study, we sought to explore the role of Gs-dependent signaling in postnatal β-cell development., Methods: To study Gs-dependent signaling, we generated conditional knockout mice in which the α subunit of the Gs protein (Gsα) was ablated from β-cells using the Cre deleter line Ins1
Cre . Mice were characterized in terms of glucose homeostasis, including in vivo glucose tolerance, glucose-induced insulin secretion, and insulin sensitivity. β-cell mass was studied using histomorphometric analysis and optical projection tomography. β-cell proliferation was studied by ki67 and phospho-histone H3 immunostatining, and apoptosis was assessed by TUNEL assay. Gene expression was determined in isolated islets and sorted β cells by qPCR. Intracellular cAMP was studied in isolated islets using HTRF-based technology. The activation status of the cAMP and insulin-signaling pathways was determined by immunoblot analysis of the relevant components of these pathways in isolated islets. In vitro proliferation of dissociated islet cells was assessed by BrdU incorporation., Results: Elimination of Gsα in β cells led to reduced β-cell mass, deficient insulin secretion, and severe glucose intolerance. These defects were evident by weaning and were associated with decreased proliferation and inadequate expression of key β-cell identity and maturation genes in postnatal β-cells. Additionally, loss of Gsα caused a broad multilevel disruption of the insulin transduction pathway that resulted in the specific abrogation of the islet proliferative response to insulin., Conclusion: We conclude that Gsα is required for β-cell growth and maturation in the early postnatal stage and propose that this is partly mediated via its crosstalk with insulin signaling. Our findings disclose a tight connection between these two pathways in postnatal β cells, which may have implications for using cAMP-raising agents to promote β-cell regeneration and maturation in diabetes., (Copyright © 2021 The Author(s). Published by Elsevier GmbH.. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
49. Mitochondrial cristae-remodeling protein OPA1 in POMC neurons couples Ca 2+ homeostasis with adipose tissue lipolysis.
- Author
-
Gómez-Valadés AG, Pozo M, Varela L, Boudjadja MB, Ramírez S, Chivite I, Eyre E, Haddad-Tóvolli R, Obri A, Milà-Guasch M, Altirriba J, Schneeberger M, Imbernón M, Garcia-Rendueles AR, Gama-Perez P, Rojo-Ruiz J, Rácz B, Alonso MT, Gomis R, Zorzano A, D'Agostino G, Alvarez CV, Nogueiras R, Garcia-Roves PM, Horvath TL, and Claret M
- Subjects
- Adipose Tissue metabolism, Animals, GTP Phosphohydrolases, Homeostasis, Mice, Neurons metabolism, Lipolysis, Pro-Opiomelanocortin metabolism
- Abstract
Appropriate cristae remodeling is a determinant of mitochondrial function and bioenergetics and thus represents a crucial process for cellular metabolic adaptations. Here, we show that mitochondrial cristae architecture and expression of the master cristae-remodeling protein OPA1 in proopiomelanocortin (POMC) neurons, which are key metabolic sensors implicated in energy balance control, is affected by fluctuations in nutrient availability. Genetic inactivation of OPA1 in POMC neurons causes dramatic alterations in cristae topology, mitochondrial Ca
2+ handling, reduction in alpha-melanocyte stimulating hormone (α-MSH) in target areas, hyperphagia, and attenuated white adipose tissue (WAT) lipolysis resulting in obesity. Pharmacological blockade of mitochondrial Ca2+ influx restores α-MSH and the lipolytic program, while improving the metabolic defects of mutant mice. Chemogenetic manipulation of POMC neurons confirms a role in lipolysis control. Our results unveil a novel axis that connects OPA1 in POMC neurons with mitochondrial cristae, Ca2+ homeostasis, and WAT lipolysis in the regulation of energy balance., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
50. Endogenous cortisol excess confers a unique lipid signature and metabolic network.
- Author
-
Vega-Beyhart A, Iruarrizaga M, Pané A, García-Eguren G, Giró O, Boswell L, Aranda G, Flores V, Casals G, Alonso C, Mora M, Halperin I, Carmona F, Enseñat J, Vidal O, Hu T, Rojo G, Gomis R, and Hanzu FA
- Subjects
- Biomarkers, Case-Control Studies, Cushing Syndrome diagnosis, Cushing Syndrome etiology, Cushing Syndrome metabolism, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 etiology, Diabetes Mellitus, Type 2 metabolism, Humans, Metabolome, Metabolomics, Prognosis, Severity of Illness Index, Hydrocortisone metabolism, Lipid Metabolism, Lipidomics, Metabolic Networks and Pathways
- Abstract
Chronic cortisol excess induces several alterations on protein, lipid and carbohydrate metabolism resembling those found in the metabolic syndrome. However, patients exposed to prolonged high levels of cortisol in Cushing syndrome (CS) present exceeding cardiometabolic alterations not reflected by conventional biomarkers. Using 3 ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS) platforms, we aimed to characterise the serum metabolome of 25 patients with active endogenous CS and 25 control subjects matched by propensity score (sex, BMI, diabetes mellitus type 2 (T2D), high blood pressure (HBP) and dyslipidaemia) to search for potential disease-specific biomarkers and pathways associated to the clinical comorbidities. A total of 93 metabolites were significantly altered in patients with CS. Increased levels of sulfur amino acids (AA), triacylglycerols, glycerophospholipids, ceramides and cholesteryl esters were observed. Contrarily, concentrations of essential and non-essential AA, polyunsaturated fatty acids, conjugated bile acids and second messenger glycerolipids were decreased. Twenty-four-hour urinary free cortisol (24h-UFC) independently determined the concentration of 21 lipids and 4 AA. A metabolic signature composed by 10 AA and 10 lipid metabolites presented an AUC-ROC of 95% for the classification of CS patients. Through differential network analysis, 152 aberrant associations between metabolites involved in the Lands cycle and Kennedy pathway were identified. Our data indicates that chronic hypercortisolemia confers a unique lipidomic signature and several alterations in numerous AA even when compared to patients with similar metabolic comorbidities providing novel insights of the increased cardiometabolic burden of CS. KEY MESSAGES: • Cortisol excess induces metabolic alterations beyond conventional biomarkers. • The hypercortisolism extent determines the concentration of 21 lipids and 5 aa. • Cortisol excess confers a unique metabolic signature of 20 metabolites. • Kennedy and Lands cycle are profoundly disturbed by cortisol excess., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.